-- Cipla USA Inc., a wholly-owned subsidiary of Cipla (NSE:CIPLA, BOM:500087), has received final approval from the U.S. Food and Drug Administration for its Albuterol Sulfate Inhalation Aerosol, according to a Thursday filing to the Indian stock exchanges.
The drug is a generic therapeutic equivalent of Ventolin HFA, marketed by GlaxoSmithKline.
Albuterol Sulfate Inhalation Aerosol is used to treat or prevent bronchospasm with reversible obstructive airway disease, and to prevent exercise-induced bronchospasm.
The product is expected to be launched in the first half of the financial year 2026-27 in the US.
According to IQVIA estimates, the total US albuterol market is valued at around $1.5 billion.
The company's shares were up over 3% in recent trade.